Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancerGlobeNewsWire • 10/20/23
Novartis (NVS) Suffers a Larger Drop Than the General Market: Key InsightsZacks Investment Research • 10/12/23
Novartis (NVS) Ascends But Remains Behind Market: Some Facts to NoteZacks Investment Research • 10/06/23
Novartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancerGlobeNewsWire • 10/05/23
Spin-outs on the rise as companies try to win out in desolate M&A marketProactive Investors • 10/04/23
SDZNY Stock: 7 Things to Know as Novartis Spinoff Sandoz Starts Trading TodayInvestorPlace • 10/04/23
Novartis spin-off completed as Sandoz makes subdued start on Swiss bourseProactive Investors • 10/04/23
Sandoz enters new era as standalone global leader and European champion in generic and biosimilar medicinesGlobeNewsWire • 10/04/23
Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines companyGlobeNewsWire • 10/04/23
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)GlobeNewsWire • 10/02/23